EXCLUSIVE LICENSE AND SPONSORED RESEARCH AGREEMENT between OMEROS CORPORATION and MEDICAL RESEARCH COUNCILExclusive License and Sponsored Research Agreement • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations • Delaware
This license agreement (the “Agreement”) is made effective the 31st day of October 2005 (the “Effective Date”) between Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and Medical Research Council, a United Kingdom governmental institution having a place of business at 20 Park Crescent, London, United Kingdom, W1B 1AL (“MRC”).
EXCLUSIVE LICENSE AND SPONSORED RESEARCH AGREEMENT between OMEROS CORPORATION and the UNIVERSITY OF LEICESTERExclusive License and Sponsored Research Agreement • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations • Delaware
This license agreement (the “Agreement”) is made effective the 10th day of June 2004 (the “Effective Date”) between Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and the University of Leicester, having a principal place of business at University Road, Leicester LE1 7RH, United Kingdom (“Leicester”).
LOAN AND SECURITY AGREEMENT No. V08302Loan and Security Agreement • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations • Illinois
This Loan and Security Agreement (this “Loan Agreement”), made as of September 12, 2008 by and between BlueCrest Capital Finance, L.P. (“Lender”), a Delaware limited partnership with its principal place of business at 225 West Washington Street, Suite 200, Chicago, Illinois 60606, and Omeros Corporation (“Borrower”), a Washington corporation with its principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle, WA 98101.
COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations • Delaware
This Commercial Supply Agreement (this “Agreement”) is made as of the 9th day of October, 2007 (the “Effective Date”) by and between Omeros Corporation, a Washington corporation, having its principal offices at 1420 Fifth Avenue, Suite 2600, Seattle, Washington 98101 (“Omeros”), and Hospira Worldwide Inc., a Delaware corporation, having its principal offices at 275 North Field Drive, Lake Forest, Illinois 60045 (“Hospira”). Omeros and Hospira previously entered into a Master Development Agreement, dated May 8, 2007 (the “Development Agreement”), pertaining to the development of Omeros’ pharmaceutical drug product OMS103HP-S. Omeros and Hospira now desire to enter into an agreement for the commercial supply of OMS103HP-S by Hospira to Omeros. Therefore, in consideration of the mutual covenants and obligations set forth below, Omeros and Hospira (the “Parties” and each a “Party”) agree as follows:
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations • Washington
This agreement (the “Agreement”) is made effective the 23rd day of February 2009 (the “Effective Date”) between Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and Roberto Ciccocioppo, Ph.D., having a residence at Vicolo San Silvestro n. 25, Camerino, 62032 IT (“Dr. Ciccocioppo”).
AMENDMENT dated 30 April 2007 of the SERVICES AND MATERIALS AGREEMENT dated 20 April 2007 By and between SCOTTISH BIOMEDICAL LIMITED T/A “SCOTTISH BIOMEDICAL” and OMEROS CORPORATIONServices and Materials Agreement • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations
This is an amendment (this “Amendment”) effective 30 April 2007, between Scottish Biomedical Limited T/A “Scottish Biomedical” (“Scottish Biomedical”) and Omeros Corporation (“Omeros”) of the Services and Materials Agreement dated 20 April 2007 (“the Agreement”) related to Omeros’ PDE10 program.
OMEROS CORPORATION AGREEMENT FOR ANTIBODY DEVELOPMENTAgreement for Antibody Development • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations • Washington
This Agreement for Antibody Development (this “Agreement”) is between Omeros Corporation (“Omeros”), a Washington corporation having an address at 1420 Fifth Avenue, Suite 2600, Seattle, Washington 98101, and North Coast Biologics LLC (“North Coast”), a Washington Limited Liability Company having an address at 2815 Eastlake Avenue East, #300, Seattle, Washington 98102, and is effective as of October 31, 2008 (the “Effective Date”). Omeros and North Coast may be referred to herein each as a “Party” or together as the “Parties”.
AGREEMENT FOR ANTIBODY DISCOVERY AND DEVELOPMENTAgreement for Antibody Discovery and Development • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations • California
This is an Agreement between Omeros Corporation (“Omeros”), a Washington corporation having an address at 1420 Fifth Avenue, Suite 2600, Seattle, Washington 98101, and Affitech AS (“Affitech”), having an address at Oslo Research Park, Gaustadalléen 21, N-0349 Oslo, Norway, and is effective as of July 25, 2008 (the “Effective Date”). Omeros and Affitech may be referred to herein each as a “Party” or together as the “Parties”.
DATED 20 April 2007 Scottish Biomedical Limited Telford Pavilion, Todd Campus, West of Scotland Science Park, Glasgow, G20 0XA, Scotland, U.K. “Scottish Biomedical” or “SB” and Omeros Corporation 1420 Fifth Avenue, Suite 2600 Seattle, WA 98101, U.S.A....Services and Materials Agreement • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations • Delaware
† DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION
MASTER SERVICES AGREEMENTMaster Services Agreement • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations • Washington
THIS MASTER SERVICES AGREEMENT (“Agreement”) is made and entered into effective January 27th, 2005 (the “Effective Date”), by and between NURA, Inc. (hereinafter “Nura”), having a place of business at 1124 Columbia Street, Seattle WA, 98104, USA, and ComGenex, Inc. (hereinafter “ComGenex” or “CGX), having a place of business at Zahony u 7, H-1031 Budapest, Hungary, altogether referred to as Parties.
AMENDMENT TO EXERCISE NOTICE AND RESTRICTED STOCK PURCHASE AGREEMENTSExercise Notice and Restricted Stock Purchase Agreement • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations • Washington
This Amendment to Exercise Notice and Restricted Stock Purchase Agreements (this “Agreement”) is made as of April 29, 2009 by and between Omeros Corporation, a Washington corporation (the “Company”), and Richard J. Klein (the “Purchaser”).
FUNDING AGREEMENTFunding Agreement • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations • Washington
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made as of the 15th day of October, 2004 by and among Omeros Corporation, a Washington corporation (the “Company”), the investors listed on Exhibit A hereto (the “Series E Investors”), H. Raymond Cairncross, Gregory A. Demopulos, M.D., George Kargianis, and Pamela Pierce Palmer, M.D., Ph.D., each of whom is herein referred to as a “Founder,” the holders of Series A Preferred Stock of the Company (the “Series A Preferred Stock”) listed on Exhibit B hereto (the “Series A Investors”), the holders of Series B Preferred Stock of the Company (the “Series B Preferred Stock”) listed on Exhibit C hereto (the “Series B Investors”), the holders of Series C Preferred Stock of the Company (the “Series C Preferred Stock”) listed on Exhibit D hereto (the “Series C Investors”), the holders of the Series D Preferred Stock of the Company (the “Series D Preferred Stock”) listed on Exhibit E hereto (the “Series D Investors,” and t
Drug Product Development and Clinical Supply AgreementDrug Product Development and Clinical Supply Agreement • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations • California
OMEROS CORPORATION, a corporation organized and existing under the laws of Washington, with its principal offices located at 1420 Fifth Avenue, Suite 2600, Seattle, Washington 98101 (hereinafter referred to as “CLIENT”)
EXCLUSIVE TECHNOLOGY OPTION AGREEMENTExclusive Technology Option Agreement • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations • Washington
THIS EXCLUSIVE TECHNOLOGY OPTION AGREEMENT (the “Agreement”) is made and entered into as of September 4, 2008 by and among Omeros Corporation, a Washington corporation (“Omeros”), Patobios Limited, a corporation incorporated under the laws of the Province of Ontario (“Patobios”), Susan R. George, M.D. (“Dr. George”) and Brian F. O’Dowd, Ph.D. (“Dr. O’Dowd”) and, with respect to Article VIII and Article X only, U.S. Bank National Association, as escrow agent (the “Escrow Agent”). Dr. George and Dr. O’Dowd are referred to herein each as a “Founder” and collectively as the “Founders.”
